Enliven Therapeutics Upsizes Public Offering to $400M+ to Fund Lead Drug Development

summarizeSummary

Enliven Therapeutics finalized an upsized public offering, raising approximately $400 million to fund the advancement of its lead drug candidate, ELVN-001, into Phase 3 trials and extend its cash runway into 2030.

check_boxKey Events

• Offering Finalized and Upsized

  Enliven Therapeutics finalized its public offering, raising approximately $400 million (or $460 million if the underwriters' option is fully exercised) through the sale of 8,933,334 shares of common stock and pre-funded warrants to purchase 1,733,333 shares. This represents an upsize from the initially proposed $250 million offering.

• Pricing Details

  The offering was priced at $37.50 per share for common stock and $37.499 per pre-funded warrant (with a nominal $0.001 exercise price). This was a slight premium to the last reported sale price of $37.00 on June 10, 2026, before the offering was announced.

• Significant Dilution

  The offering involves the issuance of 10,666,667 shares (common stock and shares underlying warrants), potentially increasing to 12,266,667 shares if the underwriters' option is fully exercised. This represents a potential dilution of over 20% to existing shareholders based on shares outstanding as of March 31, 2026.

• Funding for Lead Drug Candidate ELVN-001

  The net proceeds, estimated at $376.0 million (or $432.4 million with option exercise), will primarily fund ongoing research and development activities, including the advancement of ELVN-001 in ongoing and planned clinical trials across multiple lines of therapy, and initial commercial readiness activities.

auto_awesomeAnalysis

Enliven Therapeutics has finalized and upsized its public offering, raising approximately $400 million (potentially $460 million if the underwriters' option is fully exercised) through the sale of common stock and pre-funded warrants. This significant capital infusion, representing over 15% of the company's market capitalization, is crucial for funding the advancement of its lead drug candidate, ELVN-001, into planned Phase 3 clinical trials. The offering was priced at $37.50 per share, a slight premium to the last reported sale price of $37.00 on June 10, 2026, before the offering was announced, but a discount to today's market price of $45.47. This capital raise extends the company's cash runway into 2030, providing essential resources following recent positive Phase 1 data and FDA agreement for the ELVN-001 program. While highly dilutive for existing shareholders (over 20% potential dilution), the successful and upsized financing is a strong signal of the company's ability to secure funding for its critical drug development pipeline.